An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

C. Michael Gibson, Roxana Mehran, Christoph Bode, Johnathan Halperin, Freek Verheugt, Peter Wildgoose, Martin Van Eickels, Gregory Y.H. Lip, Marc Cohen, Steen Husted, Eric Peterson, Keith Fox

Research output: Contribution to journal › Article › peer-review

142 Scopus citations

Fingerprint

Dive into the research topics of 'An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

Fingerprint

Medicine & Life Sciences